MICROPARTICLE DNA VACCINE AGAINST SIV

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 目前，全球有4000多万人持续感染艾滋病毒-1，新感染的主要传播方式是性接触。开发和实施预防感染的有效疫苗是控制疾病传播的合乎逻辑的方法。猴免疫缺陷病毒(SIV)感染恒河猴是人类感染HIV的最佳动物模型。该项目的目标是测试一种新的疫苗递送形式，即应用于携带编码SIV蛋白的DNA的可生物降解微球的粘膜表面。我们将比较通过阴道或鼻腔粘膜接种DNA疫苗的猕猴在诱导抗SIV系统和粘膜免疫反应方面的效果。这些实验将产生有关疫苗技术的有用信息，该技术也可以应用于许多其他性传播疾病。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Currently, more than 40 million people worldwide are persistently infected with HIV-1, and the main mode of transmissions for new infections is by sexual contact. Development and implementation of an effective vaccine that would prevent infection is a logical approach to controlling the spread of the disease. Infection of rhesus macaques with the simian immunodeficiency virus (SIV) is the best animal model for HIV infection in humans. The goal of this project is to test a novel form of vaccine delivery, i.e., the application to a mucosal surface of biodegradable microspheres loaded with DNA encoding SIV proteins. We will compare the efficacy in inducing anti-SIV systemic and mucosal immune responses in macaques given a DNA vaccine via the vaginal or intranasal mucosa. These experiments will produce useful information about a vaccine technology that can also be applied to many other sexually transmitted diseases.